Bhavin BPharm - Kilitch Drugs Wholetime Director
| KILITCH Stock | 362.35 6.15 1.73% |
Director
Bhavin BPharm is Wholetime Director of Kilitch Drugs Limited
| Age | 49 |
| Phone | 91 22 6121 4100 |
| Web | https://www.kilitch.com |
Kilitch Drugs Management Efficiency
The company has return on total asset (ROA) of 0.0566 % which means that it generated a profit of $0.0566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0832 %, meaning that it generated $0.0832 on every $100 dollars invested by stockholders. Kilitch Drugs' management efficiency ratios could be used to measure how well Kilitch Drugs manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | DIRECTOR Age | ||
| Sandeep Budhiraja | Max Healthcare Institute | 55 | |
| Suneeta Reddy | Apollo Hospitals Enterprise | 66 | |
| Brijmohan Dhoot | Mangalam Drugs And | 74 | |
| Vineet B | Transport of | 52 | |
| Pr Misra | Fortis Healthcare Limited | N/A | |
| Anjali Rossi | Healthcare Global Enterprises | 39 | |
| Gagan Palta | Max Healthcare Institute | N/A | |
| Sangita MD | Apollo Hospitals Enterprise | 63 | |
Management Performance
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 |
Kilitch Drugs Limited Leadership Team
Elected by the shareholders, the Kilitch Drugs' board of directors comprises two types of representatives: Kilitch Drugs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kilitch. The board's role is to monitor Kilitch Drugs' management team and ensure that shareholders' interests are well served. Kilitch Drugs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kilitch Drugs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mukund Mehta, Executive MD | ||
| Bhavin BPharm, Wholetime Director | ||
| LLB BCom, Executive MD | ||
| Sunil Jain, Chief Officer | ||
| Mira Mehta, Managing Director | ||
| Pushpa Nyoupane, Company Officer | ||
| Rajesh Khatri, General Administration | ||
| Tajouddin Ansari, VPMarketing Operation |
Kilitch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kilitch Drugs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 5.46 B | ||||
| Shares Outstanding | 16.08 M | ||||
| Shares Owned By Insiders | 75.15 % | ||||
| Price To Book | 3.03 X | ||||
| Price To Sales | 3.16 X | ||||
| Revenue | 1.54 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Kilitch Stock
Kilitch Drugs financial ratios help investors to determine whether Kilitch Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kilitch with respect to the benefits of owning Kilitch Drugs security.